Spots Global Cancer Trial Database for extensive stage lung small cell carcinoma
Every month we try and update this database with for extensive stage lung small cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT03382561 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | NCT06287775 | Extensive Stage... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | NCT05339022 | Advanced Lung N... Advanced Lung S... Extensive Stage... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Best Practice Exercise Interv... Physical Therap... Quality-of-Life... Questionnaire A... Relaxation Ther... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT03382561 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | NCT04402788 | Extensive Stage... | Atezolizumab Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | NCT04560972 | Extensive Stage... | Atezolizumab Carboplatin Etoposide Protein Phospha... | 18 Years - | City of Hope Medical Center | |
| Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | NCT05161533 | Extensive Stage... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Carboplatin Cisplatin Durvalumab Etoposide Hypofractionate... Quality-of-Life... Questionnaire A... | 18 Years - | University of Washington | |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment | NCT04229381 | Advanced Lung C... Extensive Stage... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Physical Therap... Quality-of-Life... Questionnaire A... Relaxation Ther... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00453154 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | NCT04155034 | Extensive Stage... Limited Stage L... Lung Small Cell... | Magnetic Resona... Prophylactic Cr... | 18 Years - | SWOG Cancer Research Network | |
| Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | NCT04919382 | Extensive Stage... Metastatic Lung... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Atezolizumab Temozolomide | 18 Years - | Big Ten Cancer Research Consortium | |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | NCT04631029 | Extensive Stage... Malignant Solid... Metastatic Mali... | Atezolizumab Carboplatin Entinostat Etoposide | 18 Years - | National Cancer Institute (NCI) | |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer | NCT03995667 | Extensive Stage... Limited Stage L... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Questionnaire A... Tumor Treating ... | 22 Years - | OHSU Knight Cancer Institute | |
| Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | NCT05191797 | Extensive Stage... Limited Stage L... | Bomedemstat Atezolizumab | 18 Years - | University of Washington | |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | NCT03896503 | Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ... | Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | NCT04631029 | Extensive Stage... Malignant Solid... Metastatic Mali... | Atezolizumab Carboplatin Entinostat Etoposide | 18 Years - | National Cancer Institute (NCI) | |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer | NCT03995667 | Extensive Stage... Limited Stage L... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Questionnaire A... Tumor Treating ... | 22 Years - | OHSU Knight Cancer Institute | |
| Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | NCT04334941 | Extensive Stage... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Talazoparib | 18 Years - | National Cancer Institute (NCI) | |
| Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | NCT04728230 | Extensive Stage... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Carboplatin Durvalumab Etoposide Olaparib Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | NCT04728230 | Extensive Stage... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Carboplatin Durvalumab Etoposide Olaparib Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | NCT05339022 | Advanced Lung N... Advanced Lung S... Extensive Stage... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Best Practice Exercise Interv... Physical Therap... Quality-of-Life... Questionnaire A... Relaxation Ther... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | NCT03896503 | Bladder Small C... Extensive Stage... Extrapulmonary ... Limited Stage L... Platinum-Resist... Platinum-Sensit... Prostate Small ... Recurrent Lung ... | Berzosertib Biopsy Biospecimen Col... Computed Tomogr... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00453154 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | NCT05353439 | Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ... | Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | NCT04728230 | Extensive Stage... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Carboplatin Durvalumab Etoposide Olaparib Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | NCT06110572 | Extensive Stage... Stage IV Lung C... | Carboplatin Atezolizumab Etoposide Total Body Irra... Hypofractionate... Magnetic Resona... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | NCT05161533 | Extensive Stage... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Carboplatin Cisplatin Durvalumab Etoposide Hypofractionate... Quality-of-Life... Questionnaire A... | 18 Years - | University of Washington | |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | NCT05339022 | Advanced Lung N... Advanced Lung S... Extensive Stage... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Best Practice Exercise Interv... Physical Therap... Quality-of-Life... Questionnaire A... Relaxation Ther... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | NCT02899728 | Extensive Stage... | Carboplatin Cediranib Cediranib Malea... Cisplatin Etoposide Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment | NCT04229381 | Advanced Lung C... Extensive Stage... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Unresectable Lu... Unresectable Lu... | Physical Therap... Quality-of-Life... Questionnaire A... Relaxation Ther... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | NCT05353439 | Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ... | Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | NCT04696575 | Extensive Stage... | Atezolizumab Carboplatin Etoposide Lamivudine | 18 Years - | Roswell Park Cancer Institute | |
| LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | NCT04560972 | Extensive Stage... | Atezolizumab Carboplatin Etoposide Protein Phospha... | 18 Years - | City of Hope Medical Center | |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | NCT05353439 | Extensive Stage... Limited Stage L... Platinum-Resist... Platinum-Sensit... Recurrent Lung ... | Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Tazemetostat Hy... Topotecan Hydro... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
